EMR Search Tool Accelerates Site Selection, Patient Recruitment and Trial Enrollment
GLEN BURNIE, Md., July 18, 2018 /PRNewswire/ -- CSSi LifeSciences, a global full-service patient recruitment company, today announced that its MyClinicalTrial ID (MCT ID) database has expanded to over one million patients. MCT ID was developed to improve the investigator site selection and patient recruitment processes in a confidential and HIPAA-compliant manner. This increases study success by guaranteeing that only sites with patients who meet the study criteria will be selected to participate as investigative sites. Historically, the process of site selection has been extremely inefficient because there has not been any way to validate the sites' patient population against the study's inclusion/exclusion criteria. CSSi's MCT ID platform queries the site's de-identified patient records to ensure the site has the most eligible patients, specific for each study. Once the study is open for enrollment, the site can contact this list of patients who meet the study criteria in the first weeks of the study, which results in enrolling three to five times more patients in a more rapid timeframe. "This data-driven approach is helping to change the landscape of finding and enrolling patients for clinical trials in a more efficient way," said Chris Trizna, President, CSSi. "MCT ID has enabled our clients to select more qualified sites and enroll their studies faster." CSSi's MCT ID is a worthy solution for avoiding study startup and enrollment delays. For more information about CSSi and MCT ID, visit www.cssienroll.com/technology.html. About CSSi: Follow Us! Media Contact: View original content with multimedia:http://www.prnewswire.com/news-releases/cssis-myclinicaltrial-id-database-exceeds-1-million-patients-300682767.html SOURCE CSSi |